Cargando…
2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-line Therapy
BACKGROUND: Agents from the integrase inhibitor (INSTI) therapeutic class only are recommended as initial therapy for most patients with HIV. Clinicians now face a decision when treating ART-experienced patients on non-INSTI regimens: continue current therapy or switch to INSTI. Multiple factors may...
Autores principales: | Monroe, Anne K, Levy, Matthew E, Greenberg, Alan E, Moore, Richard, Keruly, Jeanne, Horberg, Michael A, Mohanraj, Bernadine, Kumar, Princy, Castel, Amanda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810575/ http://dx.doi.org/10.1093/ofid/ofz360.2170 |
Ejemplares similares
-
Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
por: Chang, Sui-Yuan, et al.
Publicado: (2016) -
Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014) -
Selected CNS Outcomes Among INSTI Antiretrovirals
por: Wohl, David, et al.
Publicado: (2017) -
The Emergence of Resistance Under Firstline INSTI Regimens
por: Xie, Zhiman, et al.
Publicado: (2022) -
1563. Incidence of Errors in an INSTI-Based Era: A Comparison of Error Rates Between Single Versus Multiple Tablet INSTI-Based Regimens in the Inpatient Setting
por: Blackmon, Kayla, et al.
Publicado: (2023)